Welcome to Markets Desk, your midday read on what's moving and why.
SpaceX is approaching a significant milestone, with index inclusion expected within days or weeks. That entry would unlock a fresh wave of institutional demand, as passive funds are required to buy in at scale. The breadth of early investor interest has already been called striking, but the structural buying hasn't even started yet.
Meanwhile, the question hanging over SpaceX is whether its massive valuation becomes a ceiling rather than a floor. History shows the largest companies by market cap tend to underperform simply because of their size — the math of compounding gets harder when the base is already enormous. Investors are weighing enthusiasm against that gravitational pull.
Shifting to pharma, AbbVie is reportedly in talks to acquire a biotech developing a promising atopic dermatitis treatment, with a price tag of nearly eleven billion dollars in cash. Atopic dermatitis is a crowded but lucrative space, and AbbVie needs pipeline depth as it continues managing life after Humira's patent cliff. A deal of this size signals the company is moving with urgency.
That's the tape. Markets Desk, signing off the floor.
